MONTREAL & AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, today announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc. (“Triumvira”). The US$5 million secured loan has a term of 1 year and will enable Triumvira to accelerate activities to bring its innovative lead program into the clinic. In addition, Triumvira shall grant Knight an exclusive license to commercialize Triumvira’s future approved products for Canada, Israel, Mexico, Colombia and for TAC01-CD19 for Israel, Mexico, Brazil and Colombia.
“We are excited to help Triumvira accelerate development of their novel platform for engineering T cells to attack cancer," said Jonathan Ross Goodman, Chief Executive Officer of Knight.
"We are thrilled both with this Knight solution to our short-term funding need and in having Knight as our proven successful Canadian, Israeli and South American distribution partner,” said Dr. Paul Lammers, President and Chief Executive Officer.
About Knight Therapeutics Inc.
Knight Therapeutics Inc.,
headquartered in Montreal, Canada, is a specialty pharmaceutical company
focused on acquiring or in-licensing innovative pharmaceutical products
for the Canadian and select international markets. Knight Therapeutics
Inc.'s shares trade on TSX under the symbol GUD. For more information
about Knight Therapeutics Inc., please visit the company's web site at www.gudknight.com
or www.sedar.com.
About Triumvira Immunologics Inc.
Triumvira Immunologics,
Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan
Bramson at McMaster University and Bloom Burton & Co., with the vision
of developing novel T cell therapies that are safer and more efficacious
than current gene therapy cancer treatments, including chimeric antigen
receptor (CAR) and engineered T cell receptor (TCR) therapies.
Triumvira’s proprietary T cell Antigen Coupler (TAC) technology recruits
the entire natural T cell receptor and is independent of the Major
Histocompatibility Complex (MHC), allowing for the development of better
therapies for a broader range of patients with solid or liquid
malignancies and with diseases other than cancer. With operations
spanning North America, Triumvira’s corporate offices are in Austin,
Texas, and its research facilities are in Hamilton, Ontario.
Knight Forward-Looking Statement
This document contains
forward-looking statements for Knight Therapeutics Inc. and its
subsidiaries. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual
results to differ materially from those contemplated by the
forward-looking statements. Knight Therapeutics Inc. considers the
assumptions on which these forward-looking statements are based to be
reasonable at the time they were prepared but cautions the reader that
these assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may ultimately
prove to be incorrect. Factors and risks, which could cause actual
results to differ materially from current expectations are discussed in
Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics
Inc.'s Annual Information Form for the year ended December 31, 2017.
Knight Therapeutics Inc. disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information or future events, except as required by law.